Drugs / HTL0030310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03847207 | Jan 2019 → Mar 2020 | — | Nxera Pharma UK Limited | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-02-20 | Nxera Pharma UK Limited | Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0030310 nxera.life ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTL0030310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03847207 ↗ |
| Route | Subcutaneous | “A single subcutaneous injection of HTL0030310 or placebo will be administered.” NCT03847207 ↗ |